Allarity Therapeutics, Inc. (ALLR) News
Track canonical SquawkNews coverage tagged to ALLR, Allarity Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Shares of Lobo Technologies Ltd (NASDAQ: LOBO ) rose sharply in pre-market trading after the company reported a year-over-year increase in H1 financial results. Lobo EV Technologies posted a H1 loss of 7 cents per share,
LIVE | Sep 21, 2026, 09:01 AM UTC
L
Allarity Therapeutics wins Japanese patent for stenoparib diagnostic
The company said Japan's patent office granted a key patent for its stenoparib-specific DRP® companion diagnostic, extending protection in Japan into 2039.
EQUITY | Sep 16, 2026, 12:03 PM UTC
L
Allarity Therapeutics, Inc. Secures Japan Patent for Stenoparib DRP to 2039
Allarity Therapeutics received a Japanese patent for its stenoparib-specific DRP companion diagnostic, with protection into 2039. The patent covers methods to predict benefit from stenoparib and to select patients using
NEWS | Sep 15, 2026, 12:03 PM UTC
L
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
TARPON SPRINGS, Fla., September 15, 2026 — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) NASDAQ:ALLR, a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiat
NEWS | Sep 15, 2026, 12:03 PM UTC
L
ALLR - Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
ALLR - Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
NEWS | Sep 15, 2026, 12:00 PM UTC
L
Allarity Therapeutics reports Q2 2026 results; Stenoparib Phase 3-ready campaign completed
Allarity Therapeutics reports second quarter 2026 results and states it has completed the Phase 3-ready Stenoparib manufacturing campaign.
EARNINGS | Aug 14, 2026, 12:00 PM UTC
L
Allarity Therapeutics Receives U.S. Patent And Trademark Office Patent For Its Drug Response Predictor Companion Diagnostic
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR ), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor
EQUITY | Jun 30, 2026, 12:04 PM UTC
M
Healthcare Stocks Move
Gainers Catheter Precision (AMEX: VTAK ) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ: ALLR ) stock increased by 8.08% to
EQUITY | Jun 22, 2026, 09:10 PM UTC